DBV Technologies (DBVT) Liabilities and Shareholders Equity (2015 - 2026)
DBV Technologies (DBVT) posted quarterly Liabilities and Shareholders Equity of $223.2 million for Q2 2026, up 55.62% year-on-year from $143.4 million in Q2 2025, and down 16.22% on a QoQ basis from $266.4 million in Q1 2026.
DBV Technologies (DBVT) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Liabilities and Shareholders Equity for 12 consecutive years, with $223.2 million the latest figure, recorded in Q2 2026.
- Quarterly Liabilities and Shareholders Equity rose 55.62% year-over-year to $223.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $833.8 million (up 136.4% YoY) and the FY2025 annual result came in at $233.7 million, up 255.94% from the prior year.
- Liabilities and Shareholders Equity retreated to $223.2 million in Q2 2026 per DBVT's latest filing, from $266.4 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for DBVT reached as high as $285.0 million in Q2 2022 and fell as low as $50.6 million in Q1 2025.
- A 5-year average of $175.9 million and a median of $186.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity tumbled 65.34% — and 2026, when it soared 426.88%.
- Year by year, Liabilities and Shareholders Equity stood at $246.5 million in 2022, then declined by 25.77% to $183.0 million in 2023, then plunged by 64.12% to $65.7 million in 2024, then soared by 255.94% to $233.7 million in 2025, then dropped by 4.49% to $223.2 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $223.2 million, $266.4 million, and $233.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 223.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 223.20 Mn |
| Mar 31, 2026 | 266.40 Mn |
| Dec 31, 2025 | 233.70 Mn |
| Sep 30, 2025 | 110.50 Mn |
| Jun 30, 2025 | 143.43 Mn |
| Mar 31, 2025 | 50.56 Mn |
| Dec 31, 2024 | 65.66 Mn |
| Sep 30, 2024 | 93.06 Mn |
| Jun 30, 2024 | 114.19 Mn |
| Mar 31, 2024 | 145.90 Mn |
| Dec 31, 2023 | 182.99 Mn |
| Sep 30, 2023 | 189.78 Mn |
| Jun 30, 2023 | 217.52 Mn |
| Mar 31, 2023 | 232.93 Mn |
| Dec 31, 2022 | 246.52 Mn |
| Sep 30, 2022 | 248.12 Mn |
| Jun 30, 2022 | 284.98 Mn |
| Mar 31, 2022 | 117.58 Mn |
| Dec 31, 2021 | 146.72 Mn |
| Sep 30, 2021 | 170.92 Mn |